As of 2026-09-19, the EV/EBITDA ratio of Aclaris Therapeutics Inc (ACRS) is -8.96. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Aclaris's latest enterprise value is 735.00 mil USD. Aclaris's TTM EBITDA according to its financial statements is -82.04 mil USD. Dividing these 2 quantities gives us the above Aclaris EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.3x - 13.4x | 8.8x |
| Forward P/E multiples | 11.7x - 15.8x | 14.2x |
| Fair Price | (6.74) - (7.72) | (6.63) |
| Upside | -224.7% - -243.0% | -222.8% |
| Date | EV/EBITDA |
| 2026-09-16 | -8.82 |
| 2026-09-15 | -9.17 |
| 2026-09-14 | -9.37 |
| 2026-09-11 | -8.82 |
| 2026-09-10 | -9.14 |
| 2026-09-09 | -9.23 |
| 2026-09-08 | -10.08 |
| 2026-09-04 | -10.27 |
| 2026-09-03 | -9.89 |
| 2026-09-02 | -10.29 |
| 2026-09-01 | -10.01 |
| 2026-08-31 | -10.06 |
| 2026-08-28 | -10.00 |
| 2026-08-27 | -10.25 |
| 2026-08-26 | -10.30 |
| 2026-08-25 | -10.89 |
| 2026-08-24 | -10.51 |
| 2026-08-21 | -10.68 |
| 2026-08-20 | -10.54 |
| 2026-08-19 | -10.73 |
| 2026-08-18 | -10.50 |
| 2026-08-17 | -9.84 |
| 2026-08-14 | -9.61 |
| 2026-08-13 | -9.74 |
| 2026-08-12 | -9.71 |
| 2026-08-11 | -9.84 |
| 2026-08-10 | -9.81 |
| 2026-08-07 | -9.83 |
| 2026-08-06 | -10.13 |
| 2026-08-05 | -10.59 |
| 2026-08-04 | -9.95 |
| 2026-08-03 | -9.18 |
| 2026-07-31 | -8.62 |
| 2026-07-30 | -8.82 |
| 2026-07-29 | -8.48 |
| 2026-07-28 | -8.84 |
| 2026-07-27 | -8.91 |
| 2026-07-24 | -8.67 |
| 2026-07-23 | -9.09 |
| 2026-07-22 | -9.33 |
| 2026-07-21 | -9.45 |
| 2026-07-20 | -9.25 |
| 2026-07-17 | -9.44 |
| 2026-07-16 | -8.89 |
| 2026-07-15 | -9.30 |
| 2026-07-14 | -9.01 |
| 2026-07-13 | -9.13 |
| 2026-07-10 | -9.26 |
| 2026-07-09 | -9.49 |
| 2026-07-08 | -9.15 |